Conclusion
You can take steps to lower excess triglycerides, LDL and cholesterol, raise HDL. You can take all the fish oil you want, and modify your diet to lower glucose and reduce insulin. You can modify your lifestyle to avoid hypertension and seek out hormone replacement therapy. But if your levels of homocysteine are excessive all of your changes were for naught. You will suffer from adverse cardiovascular consequences.
Vitamin B12 is a molecule that is vital to maintaining a healthy body. It doesn’t matter whether it proves to be a master molecule. Its presence maintains health and its absence leads to degeneration. It is a molecule that is not toxic if taken in excess. Waiting for the symptoms of malady to appear before introducing vitamin B12 to a regular supplementation protocol may engender deficits that can not be fully overcome. Adding vitamin B12 to a supplementation protocol designed to maintain health and vigor may avoid many of the potentialities discussed herein. Vitamin B12 is by no means a panacea but neither is it snake oil. It is simply a vital molecule of which four out of every ten people are lacking.
References:
1 – Walker III, Sydney, Dose of Sanity, New York: John Wiley & Sons, 1996 p. 192
2 – Lopponen, M., et al., Diagnosing cognitive impairment and dementia in primary health care – a more active approach is needed, Age and Ageing, 32(6):606-12
3 – Norman, E.J., Vitamin B12 deficiency, Journal of Family Practice (1993), 36:597
4 – Interview with mark Goodman in Clinical Pearls News (1997), 7(10):132-134
5 – Reid, S.D., Pseudodementia in a twenty-one year old with bipolar disorder and vitamin B12 and folate deficiency, West Indian Medical Journal (2000), 49(4):347-8
6 – Clarke R., et al., Folate, vitamin B12 and serum total homocysteine levels in confirmed Alzheimer’s disease, Archives of Neurology (1998), 55:1449-55
7 – McCaddon, A., Familial Alzheimer’s disease and vitamin B12 deficiency, Age and Ageing (1994), 23(4):335-7
8 – Wang, HX. et al., Vitamin B12 and folate in relation to the development of Alzheimer’s disease, Neurology 2001, 56:1188-94
9 – Meins, W. et al., Subnormal serum vitamin B12 and behavioural and psychological symptoms in Alzheimer’s disease, International Journal of Geriatric Psychiatry (2000), 15(5):415-8
10 – Wilhelm, H., Grodd, W., Scheifer, U. and Zrenner, E., Uncommon chiasmal lesions: demyelinating disease, vasculitis and cobalamin deficiency, German Journal of Ophthalmology 1993, 2:234-40
11 – Hotchkiss, J., A Controversial Vitamin (conference presentation), June 2001, Society for Orthomolecular Medicine, San Francisco
12 – Physician information posted on the Neurology and neurosurgery Forum in answer to a question. Questions answered by physicians from the Clevaland Clinic
13 – The writings and reports of Sally M. Pacholok, R.N. (a studied expert on the topic of Vitamin B12 Misdiagnoses)
14 – Goodikin, D.E. et al., Serum cobalamin deficiency is uncommon in multiple sclerosis, Internal Medicine 1994, 33:82-86
15 – Norman, E. J., Cobalamin (vitamin B12) deficiency identified in young Caucasion women, Blood, 2000 96(11):8b
16 – Payinda, G. and Hansen, T., Vitamin B(12) deficiency manifested as psychosis without anemia, America Journal of Psychiatry 2000, 157:660-61
17 – Penninx, B.W., et al., Vitamin B12 deficiency and depression in physically disabled older women: Epidemiologic evience from the Women’s Health and Aging Study, American Journal of Psychiatry 2000 May;157(5);715-21
18 – Tiemeier, H., et al., Vitamin B12, folate and homocysteine in depression: The Rotterdam Study, American Journal of Psychiatry 2002, 159(12):2099-101
19 – Daynes, G. , Cyanocobalamin in postpartum psychosis, South Africa Medical Journal 1975, 49(34):1373
20 – Middleman, A. B., et al., A routine CBC leads to a non-routine diagnosis, Adolescent Medicine 1996, 7(3):423-6
21 – Goggans, F.C., A case of mania secondary to vitamin B12 deficiency, American Journal of Psychiatry 1984 141(2):300-1
22 – Nygard, O. et al., Plasma homocysteine levels and mortality in patients with coronary artery disease, New England Journal of medecine 1997, 337:230-6
23 – O’Callaghan P., et al., Update on homocysteine, Heartwise (Irish heart Foundation), Winter 2000
24 – Booth, G. L. and Wang, E. E., Preventative halth care 2000 update: Screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events, The Canadian Task Force on Preventative Health care, Canadian medical Association Journal 2000, 163(1):21-9
25 – Kark, J.D., et al., Plasma homocysteine and parental myocardial infarction in young adults in Jerusalem, Circulation 2002, 105(23):2725-9
26 – Stubbs, P.J., et al., Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes, Circulation 2000, 102:605-10
27 – Wald, D.S., et al., Homocysteine and cardivascular disease: Evidence on causality from a meta-analysis, British Medical Journal 2002, 325:1202
28 – Kittner, S.J., et al., Homocyst(e)ine and risk of cerebral infarction in a biracial population: The stroke prevention in young women study, Stroke 1999, 30(8):1554-60
29 – Sato, Y., et al., Hyperhomocysteinemia in Japanese patients with convalescent stage ischemic stroke: Effect of combined therapy with folic acid and mecobalamine, Journal of the Neurological Sciences 2002, 202(1-2):65-8
30 – MacMahon, M., et al., Nutrition, Metabolism, and Cardiovascular Diseases 2000, 10(4):195-203
31 – Schnyder, G., et al., Effect of homocysteine-lowering therapy with folic acid, vitamin B(12), and vitamin B(6) on clinical outcome after percutaneous cornary intervention, The Swiss Heart Study: a randomized controlled trial, Journal of the American Medical Association 2002, 288(8):973-9
32 – Schnyder, G., et al., Decreased rate of coronary restenosis after lowering of plasma homocysteine levels, New England Journal of Medicine 2001, 345(22):1593-600
33 – Chambers, J.C., et al., Improved vascular endothelial function after oral B vitamins. An effect mediated through reduced concentrations of free plasma homocysteine, Circulation 2000, 102:2479-83
34 –
Homocysteine.. Newly proven risk factor for heart attacks
35 – Nexo, E., Cobalamin binding proteins. In: Krautler B., et al., Vitamin B12 and B12 proteins, La Jolla: Wiley; 1998 p. 461-75
36 – Wheatley, Carmen, A scarlet pimpernel for the resolution of inflammation? The role of supra-therapeutic doses of cobalamin, in the treatment of systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic or traumatic shock, Medical Hypotheses (2006) 67, 124–142
37 – Birch, C. S., et al., A novel role for vitamin B12: Cobalamins are intracellular antioxidants in vitro, Free Radical Biology & Medicine 47 (May 2009) 184-188
38 – Rothenberg, S.; Quadros, E.; Regec, A., Transcobalamin II, In Chemistry and Biochemistry of B12 (ed R. Banerjee) pp441–473. Wiley, New York; 1999
39 – Kalra, S.; Ahuja, R.;Mutti, E.; Veber, D.; Seetharam, S.; Scalabrino, G.; Seetharam, B., Cobalamin-mediated regulation of transcobalamin receptor levels in rat organs, Arch. Biochem. Biophys. 463:128–132; 2007
40 – Scalabrino, G.; Carpo, M.; Bamonti, F.; Pizzinelli, S.; D’Avino, C.; Bresolin, N.; Meucci, G.; Martinelli, V.; Comi, G. C.; Peracchi, M., High tumor necrosis factor-alpha levels in cerebrospinal fluid of cobalamin-deficient patients, Ann. Neurol. 56: 886–890; 2004
41 – McCaddon, A.; Regland, B.; Hudson, P.; Davies, G., Functional vitamin B12 deficiency and Alzheimer disease, Neurology 58:1395–1399; 2002
42 – Ginnan, R.; Guikema, B. J.; Halligan, K. E.; Singer, H. A.; Jourd’heuil, D., Regulation of smooth muscle by inducible nitric oxide synthase and NADPH oxidase in vascular proliferative diseases, Free Radic. Biol. Med. 44:1232–1245; 2008
43 – Biswas, S.; Chida, A. S.; Rahman, I., Redoxmodifications of protein-thiols: emerging roles in cell signaling, Biochem. Pharmacol. 71:551–564; 2006
44 – Vitvisky, V.;Mosharov, E.; Tritt, M.; Ataullakanov, F.; Banerjee, R., Redox regulation of homocysteine-dependent glutathione synthesis, Redox Rep. 8:57–63; 2003
45 – Olesen H, Andersen MP, Amris A., Serum vitamin B12 binding capacity in patients with anaemia, Scand J Haematol 1968;5:235–40
46 – Ghosh K, Mohanty D, Rana KS, et al., Plasma transcobal- amins in haematological disorders, Folia Haematol Int Mag Klin Morphol Blutforsch 1986;113:766–75
47 – Fenton WA, Rosenberg LE., Inherited disorders of cobalamin transport and metabolism. In: Scriver CR, Badet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease, New York: McGraw-Hill; 1995. p. 3129–50
48 – Yacoub M, Faure H, Morena M, et al., L‘intoxication cyanhydrique aigue Donnees actuelles sur le metabolisme du cyanure et le traitement par hydroxocobalamine, J Europ de Toxicol 1974;7:22–9 [In French]
49 – Motin J, Bouletrean P, Rouzious JM., Intoxication cyanhydrique grave traitee avec succes par hydroxocobalamine, J Med de Strasbourg 1970;I:717–22 [In French]
50 – Tassan H, Joyon D, Richard T, et al., Intoxication au cyanure de potassium traitee par l’hydroxocobalamine, Ann Fr Anesth Reanim 1990;9:383–5 [In French]
51 – Brouard A, Blaisot B, Bismuth C., Hydroxocobalamine in cyanide poisoning, J de Toxicol Clin et Exp 1987;7:155–68
52 – Forsyth JC, Mueller PD, Becker CE, et al., Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers, Clin Toxicol 1993;31:277–94
53 – Riou B, Gerard JL, Drieu la Rochelle C, et al., Hemodynamic effects of hydroxocobalamin in conscious dogs, Anaesthes 1991;74:552–8
54 – Hall AH, Rumack BH., Hydroxocobalamin/sodium thiosulfate as a cyanide antidote, J Emerg Med 1987;5:115–21
55 – Bodian M., Neuroblastoma. Pediatr Clin North Am 1959;6:449–72
56 – Ermens AA, Vlasveld LT, van Marion-Kievit JA, Lensen CJ, Lindemans J., The significance of an elevated cobalamin concentration in the blood, Ned Tijdschr Geneeskd 2002;146(10):459–64
57 – Geissbuhler P, Mermillod B, Rapin CH., Elevated serum vitamin B12 levels associated with CRP as a predictive factor of mortality in palliative care cancer patients: a prospective study over five years, J Pain Symptom Manage 2000;20(2):93–103
58 – Hultdin J, Van Guelpen B, Bergh A, Hallmans G, Stattin P., Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study, Int J Cancer 2005;113(5): 819–24
59 – Nishizawa Y, Yamamoto T, Terada N, Fushiki S, Matsumoto K, Nishizawa Y., Effects of methylcobalamin on the proliferation of androgen-sensitive or estrogen-sensitive malignant cells in culture and in vivo Int J Vitam Nutr Res 1997;67(3):164–70
60 – Liteplo RG, Hipwell SE, Rosenblatt DS, Sillaots S, Lue-Shing H., Changes in cobalamin metabolism are associated with the altered methionine auxotrophy of highly growth autonomous human melanoma cells, J Cell Physiol 1991;149(2): 332–8
61 – Fiskerstrand T, Christensen B, Tysnes OB, Ueland PM, Refsum H., Development and reversion of methionine dependence in a human glioma cell line: relation to homocysteine remethylation and cobalamin status, Cancer Res 1994;54(18):4899–906
62 – Yamashiki M, Nishimura A, Kosaka Y., Effects of methylcobalamin (vitamin B12) on in vitro cytokine production of peripheral blood mononuclear cells, J Clin Lab Immunol 1992;37:173–82
63 – Cytokines as mediators in the pathogenesis of septic shock. In: Rietschel ET, Wagner H, editors, p. 133–65
64 – Wheatley, Carmen, A scarlet pimpernel for the resolution of inflammation? The role of supra-therapeutic doses of cobalamin, in the treatment of systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic or traumatic shock, Medical Hypotheses (2006) 67, 124–142
65 – Wheatley, Carmen (2007), The return of the Scarlet Pimpernel: cobalamin in inflammation II — cobalamins can both selectively promote all three nitric oxide synthases (NOS), particularly iNOS and eNOS, and, as needed, selectively inhibit iNOS and nNOS, Journal of Nutritional & Environmental Medicine,16:3,181 — 211
66 – Wheatley, Carmen (2007), Cobalamin in inflammation III — glutathionylcobalamin and methylcobalamin/adenosylcobalamin coenzymes: the sword in the stone? How cobalamin may directly regulate the nitric oxide synthases, Journal of Nutritional & Environmental Medicine,16:3,212 — 226
67 – Wu, K., et al., A prospective study on folate, B12 and pyridoxal 5′-phosphate (B6) and breast cnacer, Cancer Epidemiology, Biomarkers and Prevention 1999, 8(3):209-17
68 – Alberg, A.J., et al., The risk of cervical cancer in relation to serum concentrations of folate, vitamin B12 and homocysteine, Cancer Epidemiology, Biomarkers and Prevention 2000, 9(7):761-4
69 – Sedjo, R. L., et al., Human papillomavirus persistence and nutrients involved in the methylation pathway among a cohort of young women, Cancer Epidemiology, Biomarkers and prevention 2002, 11(4):353-9
70 – Weinstein, S.J., et al., Elevated serum homocysteine levels and increased risk of invasive cervical cancer in US women, Cancer Causes and Control 2001, 12(4):317-24
71 – Piyathilake, C.J., et al., Localized folate and vitamin B-12 deficiency in squamous cell lung cancer is associated with global DNA hypomethylation, Nutrition and Cancer 2000, 37(1):99-107
72 – Carley, K. W., et al., Diet and oral premalignancy in female south Indian tobacco and betel chewers: A case-control study, Nutr Cancer 1994, 22(1):73-84
73 – Choi, Sang-Woon, Vitamin B12 deficiency: A new risk factor for breast cancer?, Nutrition Reviews 1999, 57(8):250-53